Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.

Abstract: A composition for manufacture of hard hydroxypropyl methyl cellulose capsules comprising a film forming material of hydroxypropyl methyl cellulose having a methoxy content of 27.0-30.0% (w/w), and a hydroxypropoxy content of 4.0-7.5% and as a 2% weight solution, a viscosity of 3.5-6.0 cPs at 20° C., dipping compositions, process for manufacture of hard hydroxypropyl methyl cellulose capsules according to a dip coating process and hard capsule shells.

Abstract: The present invention provides an improved method of administering a medicinal, dental or nutritional agent to a non-human animal, such as a domesticated dog or cat. The method comprises mixing a liquid composition in a mixer at various speeds and pressures for a period of time; pouring the liquid composition onto a conveyor belt propelled by polymer rollers, wherein the polymer rollers allow the components to advance on the conveyor belt without adhering to the belt; evenly distributing the composition on the belt with the use of a knife; heating the composition in one or more hot-air chambers; obtaining a film comprised of the composition; cutting the film into strips; and then administering one or more of the strips to the non-human animal by placing the strip under the tongue of the animal, i.e., by sub-lingual administration.

Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.

Abstract: The present invention provides the agricultural chemical-spreading agent composition, containing: (A) a polysaccharide in an amount of 5 to 30% by weight; (B) a polyoxyalkylene sorbitan fatty acid ester in an amount of 5 to 40% by weight; and (C) at least one nonionic surfactant selected from polyoxyalkylene alkyl ethers, sorbitan fatty acid esters, and silicone surfactants in an amount of 5 to 40% by weight, wherein the component (A) has a viscosity of not less than 5000 mPa·s in the form of a 5% by weight aqueous solution at 25° C., and a weight ratio of contents of the component (A) to the sum of components (B) and (C), (A)/[(B)+(C)], is 10/90 to 40/60.

Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.

Abstract: In one embodiment, a method includes making a pteredin phenyl pentanedioic (3P) formulation by providing an aqueous solution including one of more 3P molecules neutralized with one or more of an alkali, an alkali earth metal hydroxide, or an alkali carbonate; adding to the aqueous solution one of a surfactant, dispersant, or additive with the guest molecules; and non-covalently crosslinking the 3P formulation by exposing the 3P formulation to an excess solution of multivalent cation salt.

Abstract: The present invention relates to a cosmetic composition for massage, and more particularly, to a cosmetic composition for massage that provides a smooth rolling sensation even with a low oil content by controlling the ratio and content of polar and nonpolar oils and properly penetrates into the skin according to the control of the absorption rate by using a gum, which solves the problems with the existing massage compositions such as greasiness caused by a high content of oily ingredients and inconvenience associated with a need for cleansing the skin after use.

Abstract: The present application relates to organosilicones and compositions such as consumer products comprising such organosilicones, as well as processes for making and using such organosilicones and such compositions. Such compositions comprising such organosilicones are easier to formulate, and provide more economical and superior care benefits when compared to current silicone containing compositions.

Abstract: A method for treating a keratinous substrate comprising contacting the keratinous substrate with a composition containing at least one emulsifying agent comprising at least two different polysaccharides and at least one nonionic surfactant; at least one gelling agent; optionally, at least one film former, and a cosmetically acceptable carrier; wherein the composition exhibits an enhanced elastic property and the composition possesses a whipped texture.

Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.

Abstract: A clear soft vegetarian dosage capsule comprising a first and second biphasic film. The first biphasic film has a plurality of first reservoirs and further comprises a polysaccharide, a seaweed extract, a rheology modifier, a buffer and a plasticizer. The second biphasic film has a plurality of second reservoirs having a formulation identical to the first film to ensure a sealing engagement. A dosage amount is disposed in each of the plurality of the reservoirs forming a plurality of filled reservoirs. The dosage amount is an emulsion, oil, hydrophilic liquid. The first film is extruded or overlaid with the second film allowing each of the plurality of second reservoirs to overlay the filled reservoirs and sealed with pressure and a fusion temperature slightly less than the melting point of the first and second films forming clear soft vegetarian dosage capsules that are blown dry, bonding moisture to the polysaccharide.

Abstract: A sustained release composition comprising spray dried particles of at least one polysaccharide gum and at least one polyhydric sugar alcohol, as well as methods of making the sustained released composition are provided. A sustained release pharmaceutical solid dosage form, and a method of making the solid dosage form by compression are also provided.

Abstract: The invention relates especially to a composition in the form of an oil-in-water emulsion comprising an inner fatty phase and an outer aqueous phase and containing: a) at least 0.01% by weight and preferably at least 0.05% by weight, relative to the total weight of the composition, of at least one inulin modified with hydrophobic chains, and b) at least 0.05% by weight and preferably at least 0.1% by weight, relative to the total weight of the composition, of at least one thickening polysaccharide of plant origin, the said composition being free of silicones. The invention also relates to a cosmetic process using the said composition.

Abstract: An oral pharmaceutical formulation comprising iota-carrageenan, one or more neutral gelling polymers and a basic pharmaceutically active ingredient; which formulation inhibits the release of the basic pharmaceutically active ingredient from the formulation at acidic pH; a process for the manufacture of said formulation; and the use of said formulation in medicine.

Abstract: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.

Abstract: pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.

Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.

Abstract: Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes and/or the delivery of pharmaceutically active compounds to mucosal surfaces for topical treatment or transfer to the systemic circulation.

Abstract: Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes, especially mucositis.

Abstract: This invention is directed to novel ocular agent delivery systems and, in particular, emulsions and molecular dispersions in the form of a gel comprising a hydrophobic ocular agent.

Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.

Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.

Abstract: The present invention provides a pharmaceutical composition comprising at least one pharmaceutically acceptable bismuth-containing compound, at least one pharmaceutically acceptable non-clay-derived suspending agent, and water. The suspension exhibits reduced upward pH drift by comparison with an otherwise similar suspension which comprises a clay-derived suspending agent. Such compositions are useful in the prevention and treatment of gastrointestinal diseases and/or disorders.

Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.

Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.

Abstract: Described are heat stable aqueous solutions or gels comprising a biologically effective amount of a protein and an effective stabilizing amount of a polysaccharide gum as well as heat stable solutions or gels suitable for use in an implantable drug delivery device at body temperature. Also disclosed are lyophilized compositions having biologically activity, where such lyophilized compositions are formed by lyophilizing the stabilized solutions or gels of the invention.

Abstract: The invention relates to a nutritional intervention composition in powder form that is taken before a meal and that extends post meal satiety. The compositions of the invention are comprised of at least one protein, C12-18 fatty acids, preferably oleic acid, all of which stimulate CCK release in the body, and a source of proteinase inhibitor which acts to prevent the deactivation of CCK. The subject compositions preferably additionally contain a source of calcium and are advantageous in that they utilize a source of proteinase inhibitor as opposed to the more costly extracts. The source of proteinase inhibitor is advantageously an extract of potato, soy, or beans containing about 10 weight percent of proteinase inhibitor. The powder compositions are mixed with a suitable liquid, preferably water, prior to ingestion.

Abstract: Encapsulation compositions in which an encapsulate (A) is encapsulated in a matrix (B) may be prepared by: (i) mixing matrix (B) with a liquid plasticizer and encapsulate (A) in an extruder, to obtain a melted mixture of encapsulate (A) and matrix (B); and (ii) extruding the melted mixture, to obtain an extruded mixture.

Abstract: A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.

Abstract: Microencapsulated and/or enteric coated compositions containing a mixture of sorbents with specific adsorption affinities for uremic toxins including ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules and a bacterial source which metabolizes urea and ammonia are provided. Also provided are methods of using these compositions to alleviate symptoms of uremia in patients.

Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.

Abstract: A method for strengthening a hydrogel of a naturally-occurring gelling agent, or a derivative thereof, including the step of adding at least one glycol to the gelling agent of the general formula: HO—(CH2)n—OH, HO—(CH2—CH2O)x—H, HO—(CH2—CH2—CH2O)y—H; and, HO—(CH2—CH[CH3]—O)y—H, in which, n is from 2 to about 8; x is from 6 to about 30; and, y is from 4 to about 20. Also useful of those of the general structure: HO—[C(R1)(R2)—C(R3)(R4)]—OH, in which, R1, R2, R3, R4 are capable of being —H in all four positions, or H in 0, 1, 2, 3 positions and —CH3 or —C2H5 in any or all of the non-H occupied positions.

Abstract: Pharmaceutical compositions having improved bioadhesive properties are produced by combining an alginate, xanthan gum and/or a carageenan gum and a glucomannan and/or a galactomannan. The composition can provide both a protecting and a healing effect on mucosal surface.

Abstract: Disclosed herein is a tableted oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.

Abstract: A pharmaceutical composition for controlled onset and sustained release of an active ingredient, said composition comprising: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic carrier; (c) a hydrodynamic diffusion enhancer; and optionally (d) conventional pharmaceutically acceptable excipients selected from the group consisting of binders, fillers and lubricants and combinations thereof; and (ii) a functional coating membrane surrounding said core.

Abstract: A process for feeding an animal a diet which alters the function and morphology of the gastrointestinal tract (GIT), a large lymphoid organ in the animal and which improves glucose metabolism, satiety, and nutrient absorption. The process involves feeding a companion animal such as, for example, a dog or cat a diet of a pet food composition containing fermentable fibers which have an organic matter disappearance (OMD) of 15 to 60 percent when fermented by fecal bacteria for a 24 hour period, the fibers being present in amounts from about 1 to 11 weight percent of supplemental total dietary fiber. The animal is maintained on the diet for a sufficient period of time to allow the fermentable fibers to ferment in the GIT of the animal.

Abstract: The invention relates to a nutritional intervention composition that enhances and extends satiety in a calorically efficient manner. In particular, the invention contains protein, long chain fatty acids, calcium, soluble and insoluble fibers to stimulate CCK and prevent its subsequent inactivation and inhibition. By stimulating CCK and extending satiety the method is useful for the treatment of overweight individuals, individuals with Type II diabetes and individuals with bulimia.

Abstract: A formulation comprising lactoperoxidase, thiocyanate and/or iodide and a hydrogen peroxide donor system, in particular glucose oxidase and glucose, is useful for controlling plant-pathogenic microorganisms such as fungi and bacteria. Preferably the formulation also contains an oil.

Abstract: Application-ready pesticide compositions having enhanced pesticidal efficacy and methods for formulating such compositions are described. Pesticide concentrates are diluted with water purified to have a total dissolved solids content of 1 to about 100 ppm. The resulting application-ready pesticide compositions can be formulated at less than label-specified concentrations and/or applied at less than label-specified volume per area rates without loss of pesticidal efficacy. The application-ready compositions can be substantially free of adjuvants, or they can be optimized using polymer or ammonia based adjuvants to improve dosage transfer. Novel aqueous diluents comprising such adjuvants and low TDS water are also described.

Abstract: Film-forming compositions are disclosed that can comprise, on a dry solids basis, 25 to 75 percent by weight of certain starch derivatives having a DE less than about 1, 25 to 75% plasticizer, and 0.1 to 15% hydrocolloid gum. The starch derviatives can be chemically modified starches which range in molecular weight from 100,000 to 2,000,000. These starch-based systems can completely replace gelatin in edible film-forming applications such as soft and hard gel capsules.

Abstract: The present invention relates to a novel pharmaceutical composition and process for preparing swallowable methylcellulose tablets that disintegrate rapidly and meet USP standards in 0.1N hydrochloric acid as well as water.

Abstract: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug, xanthan gum and a water-soluble calcium salt in an amount sufficient to make the fluoroquinolone antibiotic drug and xanthan gum compatible are disclosed.

Abstract: Topical skin rejuvenation cream and lotion compositions for dry, damaged or aging skin comprising deionized water, mink oil, vitamin E, retinol acetate (vitamin A), ginseng, aloe vera, glycerin, lanolin (hydrous), gotu kola, soybean oil, fish liver oil, hydrolyzed animal protein, dl-alpha tocopherol acetate, stearic acid, cetyl alcohol, citric acid, silicon, isopropylmyristate, propylene glycol, stearyl alcohol, glycerol stearate, dimethicone, lactic acid, quaternium-15, propylparaben, carbomer 934 and 940, triethanolamine, methylparaben, tetrasodium ethylenediaminetetraacetic acid (EDTA), DMDM hydantoin, diazolidinyl urea and fragrance.

Abstract: A method for preparing solid rapidly disintegrating dosage forms shaped as biconvex tablets having symmetrical top and bottom surfaces and dosage forms obtainable thereby.

Abstract: A topical composition for impregnating a bandage comprises zinc oxide in a stable oil in water emulsion. The emulsion comprises one or more fats or oils, one or more emulsifying agents, at least one water soluble gum and water. No preservative is required.

Abstract: A pharmaceutical composition has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is selected from hydroxypropylcellulose (HPC), ethylcellulose (EC), or derivatives of HPC, EC, and hydroxyethylcellulose (HEC) and the second component is at least one other polymer. When HPC is the first component, hydroxypropylmethylcellulose (HPMC), HEC, or carboxymethylcellulose will not be the second component and when EC is the first component, HPMC will not be the second component. The medicament can be a variety of drugs or nutritional supplements. The pharmaceutical composition releases the medicament for a prolonged or sustained period of time and can be formulated into many dosage forms.

Abstract: The invention relates to a nutritional intervention composition that enhances and extends satiety in a calorically efficient manner. In particular, the invention contains protein, long chain fatty acids, calcium, soluble and insoluble fibers to stimulate CCK and prevent its subsequent inactivation and inhibition. By stimulating CCK and extending satiety the method is useful for the treatment of overweight individuals, individuals with Type II diabetes and individuals with bulimia.

Abstract: A process for feeding an animal a diet which alters the function and morphology of the gastrointestinal tract (GIT), a large lymphoid organ in the animal and which improves glucose metabolism, satiety, and nutrient absorption. The process involves feeding a companion animal such as, for example, a dog or cat a diet of a pet food composition containing fermentable fibers which have an organic matter disappearance (OMD) of 15 to 60 percent when fermented by fecal bacteria for a 24 hour period, the fibers being present in amounts from about 1 to 11 weight percent of supplemental total dietary fiber. The animal is maintained on the diet for a sufficient period of time to allow the fermentable fibers to ferment in the GIT of the animal.